About the company
Flavocure Biotech Inc. aims to be a leader in transforming natural products into new cures for patients.
The company has discovered several promising new drug candidates. In collaboration with some of the most prestigious research institutions in the world, Flavocure is advancing these candidates through clinical research. Preliminary data indicate that Flavocure’s drug candidates possess activity against known driver mutations and targets implicated in cancer.
Caflanone is Flavocure’s lead drug candidate and received FDA Orphan Drug Designation in 2019 for pancreatic cancer.
In addition to pancreatic cancer, Flavocure’s drug candidates have demonstrated activity in a variety of cancers, including Glioblastoma (an aggressive form of brain cancer), Acute Myeloid Leukemia, and Multiple Myeloma.